U.S. Blood-based Biomarker For Parkinson’s Disease Market (2025 - 2033) Size, Share & Trends Analysis Report By Biomarker Type (Protein Biomarkers, Inflammatory Markers), By Technology (ELISA/Immunoassay, Multiplex Platforms), By End Use, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                    1.2. Segment Definitions
                        1.2.1. Biomarker Type
                        1.2.2. Technology
                        1.2.3. End use
                        1.2.4. Country scope
                        1.2.5. Estimates and forecasts timeline.
                    1.3. Research Methodology
                    1.4. Information Procurement
                        1.4.1. Purchased database
                        1.4.2. GVR’s internal database
                        1.4.3. Secondary sources
                        1.4.4. Primary research
                        1.4.5. Details of primary research
                    1.5. Information or Data Analysis
                        1.5.1. Data analysis models
                    1.6. Market Formulation & Validation
                    1.7. Model Details
                        1.7.1. Commodity flow analysis (Model 1)
                        1.7.2. Approach 1: Commodity flow approach
                        1.7.3. Volume price analysis (Model 2)
                        1.7.4. Approach 2: Volume price analysis
                    1.8. List of Secondary Sources
                    1.9. List of Primary Sources
                    1.10. Objectives
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                        2.2.1. Biomarker Type outlook
                        2.2.2. Technology outlook
                        2.2.3. End use outlook
                        2.2.4. Country outlook
                    2.3. Competitive Insights
Chapter 3. U.S. Blood-based Biomarker For Parkinson’s Disease Market Variables, Trends & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent market outlook
                        3.1.2. Related/ancillary market outlook.
                    3.2. Market Dynamics
                        3.2.1. Market driver analysis
                        3.2.2. Market restraint analysis
                    3.3. U.S. Blood-based Biomarker For Parkinson’s Disease Market Analysis Tools
                        3.3.1. Industry Analysis – Porter’s
                        3.3.2. PESTEL Analysis
Chapter 4. U.S. Blood-based Biomarker For Parkinson’s Disease Market: Biomarker Type Estimates & Trend Analysis
                    4.1. Biomarker Type Market Share, 2024 & 2033
                    4.2. Segment Dashboard
                    4.3. U.S. Blood-based Biomarker For Parkinson’s Disease Market: Biomarker Type Movement Analysis
                    4.4. U.S. Blood-based Biomarker For Parkinson’s Disease Market Size & Trend Analysis, by biomarker type, 2021 to 2033 (USD Million)
                    4.5. U.S. Blood-based Biomarker For Parkinson’s Disease Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.6. Protein Biomarkers
                        4.6.1. Protein biomarkers Market estimates and forecasts 2021 to 2033 (USD Million)
                    4.7. Inflammatory Markers
                        4.7.1. Inflammatory Markers Market estimates and forecasts 2021 to 2033 (USD Million)
                    4.8. Metabolic Markers
                        4.8.1. Metabolic Markers Market estimates and forecasts 2021 to 2033 (USD Million)
                    4.9. Transcriptomic/miRNA
                        4.9.1. Transcriptomic/miRNA Market estimates and forecasts 2021 to 2033 (USD Million)
                    4.10. Others
                        4.10.1. Others Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. U.S. Blood-based Biomarker For Parkinson’s Disease Market: Technology Estimates & Trend Analysis
                    5.1. Technology Market Share, 2024 & 2033
                    5.2. Segment Dashboard
                    5.3. U.S. Blood-based Biomarker For Parkinson’s Disease Market by Technology Outlook
                    5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
                    5.5. ELISA/Immunoassay
                        5.5.1. ELISA/Immunoassay Market estimates and forecasts 2021 to 2033 (USD Million)
                    5.6. Multiplex platforms
                        5.6.1. Multiplex platforms Market estimates and forecasts 2021 to 2033 (USD Million)
                    5.7. NGS/qPCR (genetic)
                        5.7.1. NGS/qPCR (genetic) Market estimates and forecasts 2021 to 2033 (USD Million)
                    5.8. Mass spectrometry
                        5.8.1. Mass spectrometry Market estimates and forecasts 2021 to 2033 (USD Million)
                    5.9. Others
                        5.9.1. Others Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. U.S. Blood-based Biomarker For Parkinson’s Disease Market: End use Estimates & Trend Analysis
                    6.1. End use Market Share, 2024 & 2033
                    6.2. Segment Dashboard
                    6.3. U.S. Blood-based Biomarker For Parkinson’s Disease Market by End use Outlook
                    6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
                    6.5. Academic/Research Labs
                        6.5.1. Academic/Research Labs Market estimates and forecasts 2021 to 2033 (USD Million)
                    6.6. Pharmaceutical / Biotech (for Clinical Trials)
                        6.6.1. Pharmaceutical / Biotech (for Clinical Trials) Market estimates and forecasts 2021 to 2033 (USD Million)
                    6.7. Hospitals
                        6.7.1. Hospitals Market estimates and forecasts 2021 to 2033 (USD Million)
                    6.8. Clinical Diagnostic Labs
                        6.8.1. Clinical Diagnostic Labs Market estimates and forecasts 2021 to 2033 (USD Million)
                    6.9. Others
                        6.9.1. Others Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. U.S. Blood-based Biomarker For Parkinson’s Disease Market: Country Estimates & Trend Analysis
                    7.1. Country Market Share Analysis, 2024 & 2033
                    7.2. Country Market Dashboard
                    7.3. U.S. Country Market Snapshot
                    7.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
                    7.5. U.S.
                        7.5.1. Key country dynamics
                        7.5.2. Regulatory framework/Reimbursement
                        7.5.3. Competitive scenario
                        7.5.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. Competitive Landscape
                    8.1. Recent Developments & Impact Analysis, By Key Market Participants
                    8.2. Company/Competition Categorization
                    8.3. Vendor Landscape
                        8.3.1. List of key distributors and channel partners
                        8.3.2. Key customers
                        8.3.3. Key company market share analysis, 2024
                        8.3.4. Amprion
                            8.3.4.1. Company overview
                            8.3.4.2. Financial performance
                            8.3.4.3. Biomarker Type benchmarking
                            8.3.4.4. Strategic initiatives
                        8.3.5. C2N Diagnostics
                            8.3.5.1. Company overview
                            8.3.5.2. Financial performance
                            8.3.5.3. Biomarker Type benchmarking
                            8.3.5.4. Strategic initiatives
                        8.3.6. Olink Proteomics
                            8.3.6.1. Company overview
                            8.3.6.2. Financial performance
                            8.3.6.3. Biomarker Type benchmarking
                            8.3.6.4. Strategic initiatives
                        8.3.7. Denali Therapeutics
                            8.3.7.1. Company overview
                            8.3.7.2. Financial performance
                            8.3.7.3. Biomarker Type benchmarking
                            8.3.7.4. Strategic initiatives
                        8.3.8. Biogen
                            8.3.8.1. Company overview
                            8.3.8.2. Financial performance
                            8.3.8.3. Biomarker Type benchmarking
                            8.3.8.4. Strategic initiatives
                        8.3.9. Roche / Genentech
                            8.3.9.1. Company overview
                            8.3.9.2. Financial performance
                            8.3.9.3. Biomarker Type benchmarking
                            8.3.9.4. Strategic initiatives
                        8.3.10. Verily Life Sciences
                            8.3.10.1. Company overview
                            8.3.10.2. Financial performance
                            8.3.10.3. Biomarker Type benchmarking
                            8.3.10.4. Strategic initiatives
                        8.3.11. AC Immune
                            8.3.11.1. Company overview
                            8.3.11.2. Financial performance
                            8.3.11.3. Biomarker Type benchmarking
                            8.3.11.4. Strategic initiatives
                        8.3.12. SomaLogic
                            8.3.12.1. Company overview
                            8.3.12.2. Financial performance
                            8.3.12.3. Biomarker Type benchmarking
                            8.3.12.4. Strategic initiatives
                        8.3.13. Quanterix
                            8.3.13.1. Company overview
                            8.3.13.2. Financial performance
                            8.3.13.3. Biomarker Type benchmarking
                            8.3.13.4. Strategic initiatives

List of Tables

Table 1 List of abbreviations
Table 2 U.S. Blood-based Biomarker For Parkinson’s Disease, by biomarker type, 2021 - 2033 (USD Million)
Table 3 U.S. Blood-based Biomarker For Parkinson’s Disease, by Technology, 2021 - 2033 (USD Million)
Table 4 U.S. Blood-based Biomarker For Parkinson’s Disease, by end use, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in U.S.
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 U.S. Blood-based Biomarker For Parkinson’s Disease Market: market outlook
Fig. 10 U.S. Blood-based Biomarker For Parkinson’s Disease competitive insights
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 Penetration and growth prospect mapping
Fig. 14 Industry value chain analysis
Fig. 15 U.S. Blood-based Biomarker For Parkinson’s Disease Market driver impact
Fig. 16 U.S. Blood-based Biomarker For Parkinson’s Disease Market restraint impact
Fig. 17 U.S. Blood-based Biomarker For Parkinson’s Disease Market strategic initiatives analysis
Fig. 18 U.S. Blood-based Biomarker For Parkinson’s Disease Market: Biomarker Type movement analysis
Fig. 19 U.S. Blood-based Biomarker For Parkinson’s Disease Market: Biomarker Type outlook and key takeaways
Fig. 20 Protein biomarkers market estimates and forecasts, 2021 - 2033
Fig. 21 Inflammatory markers market estimates and forecasts,2021 - 2033
Fig. 22 Metabolic markers market estimates and forecasts, 2021 - 2033
Fig. 23 Transcriptomic/miRNA market estimates and forecasts, 2021 - 2033
Fig. 24 Others market estimates and forecasts, 2021 - 2033
Fig. 25 U.S. Blood-based Biomarker For Parkinson’s Disease Market: Technology movement analysis
Fig. 26 U.S. Blood-based Biomarker For Parkinson’s Disease Market: Technology outlook and key takeaways
Fig. 27 ELISA/Immunoassay market estimates and forecasts, 2021 - 2033
Fig. 28 Multiplex platforms market estimates and forecasts, 2021 - 2033
Fig. 29 NGS/qPCR (genetic) market estimates and forecasts, 2021 - 2033
Fig. 30 Mass spectrometry market estimates and forecasts, 2021 - 2033
Fig. 31 Others market estimates and forecasts, 2021 - 2033
Fig. 32 U.S. Blood-based Biomarker For Parkinson’s Disease Market: End use movement analysis
Fig. 33 U.S. Blood-based Biomarker For Parkinson’s Disease Market: End use outlook and key takeaways
Fig. 34 Academic/Research Labs market estimates and forecasts, 2021 - 2033
Fig. 35 Pharmaceutical / Biotech (for Clinical Trials) market estimates and forecasts, 2021 - 2033
Fig. 36 Hospitals market estimates and forecasts, 2021 - 2033
Fig. 37 Clinical Diagnostic Labs market estimates and forecasts, 2021 - 2033
Fig. 38 Others market estimates and forecasts, 2021 - 2033
Fig. 39 U.S. Blood-based Biomarker For Parkinson’s Disease Market: Country movement analysis
Fig. 40 U.S. Blood-based Biomarker For Parkinson’s Disease Market: Country outlook and key takeaways
Fig. 41 U.S. Blood-based Biomarker For Parkinson’s Disease Market share and leading players
Fig. 42 U.S. market estimates and forecasts, 2021 - 2033
Fig. 43 Market share of key market players- U.S. Blood-based Biomarker For Parkinson’s Disease Market